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Abstract
Pneumonia is a complex pulmonary disease in need of new clinical
approaches. Although triggered by a pathogen, pneumonia often
results from dysregulations of host defense that likely precede
infection. The coordinated activities of immune resistance and tissue
resilience then dictate whether and how pneumonia progresses or
resolves. Inadequate or inappropriate host responses lead to more
severe outcomes such as acute respiratory distress syndrome and
to organ dysfunction beyond the lungs and over extended time
frames after pathogen clearance, some of which increase the risk
for subsequent pneumonia. Improved understanding of such host
responses will guide the development of novel approaches for
preventing and curing pneumonia and for mitigating the subsequent
pulmonary and extrapulmonary complications of pneumonia. The
NHLBI assembled a working group of extramural investigators to
prioritize avenues of host-directed pneumonia research that should
yield novel approaches for interrupting the cycle of unhealthy
decline caused by pneumonia. This report summarizes the working
group’s specific recommendations in the areas of pneumonia
susceptibility, host response, and consequences. Overarching goals
include the development of more host-focused clinical approaches
for preventing and treating pneumonia, the generation of predictive
tools (for pneumonia occurrence, severity, and outcome), and the
elucidation of mechanisms mediating immune resistance and
tissue resilience in the lung. Specific areas of research are highlighted
as especially promising for making advances against pneumonia.
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Pneumonia is a persistent, pervasive,
and difficult pulmonary disease. Lower
respiratory tract infection is the most
common infectious cause of death in the
world, responsible for almost 2.7 million
deaths yearly and 103 million disability-
adjusted life-years lost in 2015 (1). The
burden of disease consistently ranks first or
second largest worldwide, with economic
costs in the United States alone amounting
to tens of billions of dollars per year. Trends
such as increasing antibiotic resistance,
emerging pathogens, demographic shifts
toward older populations, and changes in
medical care resulting in more subjects living
in conditions that increase pneumonia risk
suggest that the pneumonia problem is
poised to worsen rather than improve.
Guidelines for community-acquired,
hospital-acquired, and ventilator-associated
pneumonias have been developed and
are being updated to aid in the clinical
management of pneumonia. However, even
accurate diagnosis can be a challenge in adult
and especially pediatric populations. Current
clinical practice is insufficient to curtail the
acute mortality and long-term consequences
of this syndrome. Pneumonia prevention
and treatment strategies need to be
complemented with novel approaches that
incorporate new and emerging knowledge.
The microbes most often triggering
pneumonia are ubiquitous and unavoidable
pathobionts rather than highly virulent
pathogens, growing in the lung to cause
pneumonia only under exceptional
circumstances. Whether pneumonia ensues
depends largely on the quality and quantity of
host response activities that defend the lung
against pneumonia. Failures of these host
defense pathways lead to pneumonia and to
poor pneumonia outcomes, including acute
respiratory distress syndrome and sepsis
(with pneumonia being the leading cause of
each syndrome). Pneumonia also leads to
pulmonary function decline and the onset or
exacerbation of cardiovascular disease (CVD;
including heart attacks, strokes, heart failure,
and atrial fibrillation), cognitive decline,
depression, physical limitation, and shortened
lifespan. Although a host–pathogen
interaction underlies this disease, key
determinants of the susceptibility to,
progression of, and outcomes of pneumonia
are driven by characteristics of the host.
Much focus has been placed on the
pathogens causing pneumonia, but a
tremendous need for research from the
perspective of the host remains.
In August 2017, the NHLBI assembled
a Working Group for Advancing
Pneumonia Research in Heart, Lung,
and Blood Diseases, comprised of a
multidisciplinary group of experts and
thought leaders in pneumonia biology and
medicine, including basic, translational,
and clinical investigators. The working
group was charged with brainstorming
about future research opportunities in
pneumonia-related heart, lung, and blood
research to help inform next steps for the
NHLBI Pneumonia Program. A specific
mandate was to identify knowledge gaps
that, if addressed, will lead to improved
understanding of the host factors
influencing pneumonia incidence and
severity; helping to guide new strategies for
lowering pneumonia risk; for preventing or
curing acute lower respiratory infections;
and for improving heart, lung, and blood
health. The working group meeting was
divided into three sessions (Figure 1)
addressing topics of pneumonia host
susceptibility, host responses, and host
consequences, followed by group
discussions of the common themes and
overarching priorities. This summary
includes topical recommendations, as well
as overarching themes that emerged as
having the greatest potential for contributing




Pneumonia associates with many host
characteristics, including age and chronic
conditions such as chronic obstructive
pulmonary disease (COPD), cystic fibrosis,
atherosclerosis, heart failure, cancer,
arthritis, Parkinson’s disease, depression,
and others. Leading risk factors for chronic
heart, lung, and other diseases are
independent risk factors for pneumonia,
including cigarette smoking, obesity,
alcohol abuse, and air pollution (2).
However, the biological pathways linking
pneumonia susceptibility and risk factors
such as aging, comorbidities, and exposures
are only beginning to be delineated
(Figure 1).
Patients at the extremes of age—the
pediatric and geriatric populations—have
increased susceptibility to pneumonia and
increased mortality, with myriad biological
changes potentially contributing to an
unclear degree (3–8). Cigarette smoke, a
major cause of COPD, has significant
pathological effects on the lung that impact
the host response to pneumonia (9, 10).
Ambient air pollution is a major risk factor
for pulmonary mortality, and respiratory
infections are exacerbated because of
exposure to environmental air pollutants,
with the greatest effects being due to
particulate matter, ozone, and nitrogen
oxides (11, 12). The increased risk of
pneumonia for patients with chronic lung
diseases such as COPD and asthma may
result from combinations of anatomic
changes, altered immune functions, and
inhaled corticosteroids (13–19). Whether
susceptibility determinants that underlie
infectious exacerbations of these chronic
lung diseases overlap those for pneumonia
is not known (20). With over one-third of
the U.S. adult population being obese (15,
21), substantial need exists to understand
















• Dysfunctions in nonpulmonary
organs
• Sequelae that persist
• Exacerbation of chronic diseases








Figure 1. Different biological processes especially relevant to distinct stages of pneumonia biology
present unique opportunities for discovery and for intervention. The working group was structured to
present the current state of the field in each of these three areas; to identify the knowledge gaps,
emerging opportunities, and the most pressing needs in each; and to determine whether and which
research priorities span all three divisions. Results are presented in the text and tables.
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infections in obesity, diabetes, and the
metabolic syndrome (22–24). Body mass
index is an inadequate surrogate, and
studies are needed to determine how
analytes such as serum leptin, insulin,
hemoglobin A1c, or lipid species associate
with pneumonia risk (21). Patients with
cancer develop a spectrum of infections
that depend on the patient’s specific
underlying immunologic defects, local
barrier defense defects, and malignancy
type (25, 26). Lymphopenia, myeloablative
and B- or T-cell–depleting chemotherapies,
graft-versus-host disease, and other factors
increase the risk of developing life-
threatening pneumonia. In patients with
lung cancer, localized airway obstruction
by tumor and radiation therapy causing
mucosal changes can predispose individuals
to pneumonia. For patients with cancer,
such structural and immunologic
abnormalities make the diagnosis of
pneumonia challenging and impact the
composition and duration of therapy.
Many of the above-mentioned
identifiable host susceptibility factors are
important in the understanding and
management of patients with pneumonia.
Research is needed to move beyond
generalizations about which broad
populations are generally prone to
pneumonia in order to develop patient
measurements that report an individual’s
risk of pneumonia. Although many
complex diseases have clear links to gene
variants, only a few genetic susceptibility
loci are identified for pneumonia
(27–29), and these need further genetic,
epidemiologic, and functional investigation.




should be explored to identify markers
and mechanistic causes of pneumonia
susceptibility. The diversity and complexity
of the patient population require
reenvisioning how patients are endotyped
for risk profiling. Identifying specific
biological biomarkers that indicate levels of
pneumonia susceptibility will be enabled
by “omics”-based technologies as well as
currently available large clinical datasets.
Although the relatively low annual
incidence of pneumonia in at-risk
populations and the ambiguities related to
pneumonia diagnosis complicate these
endeavors, efforts should be made to link
genetic and biologic data to pneumonia
rates in ongoing large population studies,
as well as to consider creative new
experimental designs for revealing
biological signs of pneumonia susceptibility.
These approaches will need to incorporate
current technologies that help better
identify and quantitate the microbial
pathogen(s) to best understand these host
susceptibility factors in the appropriate
and clinically relevant context. As etiology
becomes better understood, select defects
in host defense may emerge that result in
susceptibilities to defined subsets of
pneumonia pathogens.
To better define the critical
determinants of host susceptibility that will
help identify novel preventive strategies and
support timely initiation and augmentation
of therapy in susceptible populations, the
working group recommends the following
as priority research areas (Table 1):
1. Use biological “omics” profiles (e.g.,
transcriptomic, metabolomic,
proteomic, glycomic, metagenomic, and
other unbiased platforms) and clinical
information (such as datasets derived
from electronic health records) to
develop and test a “risk-ome” that
predicts susceptibility versus resistance
in de novo and recurrent pneumonia,
including the important cohort of
patients with chronic lung disease.
2. Broaden consideration for and testing
of human specimens collected to
examine potential biomarkers for host
susceptibility to community-acquired or
nosocomial pneumonia.
3. Define connections between select
elements of host susceptibility and
changes in the microbial pathogens
(viral, bacterial, or fungal) causing
pneumonia in adults or children,
including delineation of pneumonia
susceptibilities specific to limited types
of pathogen.
Host Response to Pneumonia
Defense against pneumonia is initiated
by and dependent on cells of the lung
(Figure 1), which work together to
accomplish immune resistance (attacking
microbes to reduce pathogen burden)
and tissue resilience (protecting the
organ’s structure and function against the
onslaughts of infection and inflammation)
(30–33). The first cells encountered by a
microbe in the lung are epithelial cells,
macrophages, and dendritic cells, making
their responses especially key to rapidly
amplifying and modulating effective
immune resistance (34–38). Lymphocytes
in the lung direct, skew, and modulate these
pulmonary defenses, including resident
memory lymphocytes (CD41 T cells, CD81
T cells, B cells, and distinct subsets thereof),
innate lymphoid cells, mucosal-associated
invariant T cells, and others making
contributions that are beginning to be
defined (8, 30). These cells and pathways
are in turn influenced by and influence the
lung microbiome (39, 40), which may
further direct pneumonia defense activities
in ways that need to be understood better.
Table 1. Recommendations Related to Stages of before, during, or after Pneumonia
Defining susceptibility to pneumonia
(before)
Develop “risk-ome” from biological profiles and/or
clinical data
Incorporate susceptibilities into diagnoses and
severity assessments
Connect susceptibilities to types of microbes
Elucidating host responses (during) Define lung cell roles in defense
Elucidate transition from inflammation to resolution/
repair stages
Compare and contrast host responses across
pathogens
Derive endotypes from biological and clinical
information
Rapidly identify those failing current clinical
approach
Understanding consequences (after) Mechanistically link lung infection to extrapulmonary
pathophysiologies
Find markers that predict specific types of decline
after clinical recovery
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Improved understanding of the
fundamental mechanisms of immune
resistance in the lung will provide new ways
to differentiate subjects with increased
pneumonia susceptibility and to develop
novel therapeutic approaches tailored to
these lung defense pathways. Tissue
resilience and the resolution of pulmonary
inflammation involve cytoprotective
pathways within lung cells (8), as well
as autocrine and paracrine signaling
mediated by proresolving eicosanoids
(33, 34). The inflection point between
the positive feedback loops amplifying
inflammation and the ensuing
resolution stages is yet to be defined, and
factors differentiating whether resolution is
fully effective or instead only partially
effective or even deleterious need to be
determined.
Emerging areas with special potential
for large impact in pneumonia host response
include 1) determining how host responses
that defend against pneumonia are altered
and improved by prior experiences with
respiratory infections and 2) using
computational biomedical approaches to
more meaningfully reveal ongoing host
responses in patients with pneumonia.
Respiratory infections are ubiquitous and
inevitable, and the pulmonary defenses of
all but the very youngest of children are
influenced by their respiratory infection
history. Although lung defenses clearly
change dramatically after the resolution of
prior infections (8, 41–43), the mechanisms
protecting these more experienced lungs
are still poorly understood. The lower
pneumonia rates in young, healthy adults
likely result from naturally acquired
heterotypic immune memory (8, 42) and
trained innate immunity (44) generated by
prior infections, but the mechanisms
remain poorly understood. Different
cellular components of the lung (particularly
resident memory lymphocytes and
innate lymphocytes), as well as
reprogrammed responses from
macrophages and epithelial cells (due to
metabolic and epigenetic alterations), are
likely responsible for the improved lung
defense, but exactly which changes occur
and contribute are largely unclear.
Dysregulation of these lung-protective
mechanisms is inferred to be responsible
for the microbial growth and physiological
dysfunction that occurs in pneumonia, but
which pathways are disrupted in which
cases remain speculative. Computational
approaches to pneumonia patient samples
reveal heterogeneity in host responses
during lung infection (45–48), and such
heterogeneity can be leveraged to provide
insights into alterations in the relevant
immunity and physiology pathways.
Establishing molecular profiles that report
variations in patients’ host responses
during pneumonia holds promise for
guiding research into mechanisms of lung
protection. Such profiles also have great
potential for endotyping patients with
pneumonia, which will improve diagnosis,
prognostication, and clinical approaches.
To incorporate the knowledge of host
responses during pneumonia as a means to
elucidate pathophysiology and improve
patient care, the working group identified
several goals (Table 1):
1. Better define the roles of specific lung
cells (including but not limited to
epithelial cells, macrophages, innate
lymphoid cells, and resident memory
lymphocytes) in host defense, with a
particular emphasis on how lung
defense is reprogramed (e.g., altered
responses from the cells) and remodeled
(e.g., different cellular constituents of
the lung) owing to the repeated microbial
and nonmicrobial exposures experienced
by the lung
2. Identify the critical determinants of the
transition from the initial phases of
amplifying acute responses to the later
phases of resolution and lung-reparative
processes in the infected lung, and
establish biological and clinical
parameters that distinguish between
appropriate versus dysregulated tissue
response and repair
3. Delineate elements of host responses
that are conserved across diverse
pneumonias or distinct to pneumonias
caused by different types of respiratory
pathogens
4. Differentiate pneumonia endotypes on
the basis of biological and clinical
information, and determine their
potential utility for guiding medical
approaches (to improve abilities to stage
disease, to gauge effects of clinical
activities, to distinguish
pathophysiologies, etc.)
5. Develop methods for using measures of
the host response to predict pneumonia
outcomes in adult and pediatric patients,




Two erroneous paradigms have limited
understanding of the role of pneumonia on
health and have compromised the research
agenda on pneumonia. The first is that
pneumonia is a localized disease. The
systemic response defined as sepsis has long
been recognized and pneumonia remains
the most common site of infection leading to
sepsis and septic shock in the general
population. Metastatic infection, such as to
pleura, bone, joints, brain, heart valves, and
the myocardium (49), explains some but
not all systemic manifestations. Pneumonia
causes systemic muscle weakness, and
interactions between acute respiratory
infection and age on skeletal muscle stress
and repair demand attention (50, 51).
During the acute episode, pneumonia
affects multiple organ systems (8), often
causing delirium, acute kidney injury,
liver injury, atrial fibrillation, and
more. Mechanisms underlying these
extrapulmonary pathophysiologies during
pneumonia currently are poorly
understood (Figure 1).
The second erroneous concept is that
pneumonia is an acute disease. In fact, some
of the clinical manifestations during the
acute episode may persist (e.g., persistent
delirium, skeletal muscle weakness, or acute
kidney injury leading to chronic kidney
disease), or preexisting chronic diseases may
be exacerbated, after hospital discharge (8).
Thus, pneumonia accelerates either
subclinical or overt chronic diseases and is
a leading cause of readmissions (52). The
role of pneumonia as a risk factor for
chronic diseases is increasingly recognized.
For example, the magnitude of risk for
CVD, including stroke and myocardial
infarction, associated with pneumonia is
similar to or higher than the risk of CVD
associated with traditional risk factors
such as cigarette smoking, diabetes, and
hypertension (53). Although amplified in
those with chronic diseases, the effect
of an episode of pneumonia on younger
and previously healthy patients is also
significant (54). Mechanisms have yet to
be definitively demonstrated for any of
the myriad long-term consequences of
pneumonia (8). Biomarkers including
cytokines associated with pathogenesis are
often not normal at the time of discharge
or when clinical “cure” has been achieved
NHLBI WORKSHOP REPORT
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(55–57). This persistent altered immune
state may represent dysregulated
resolution and lead to more chronic
manifestations such as an abnormal pro- or
antiinflammatory state, altered coagulation,
or enhanced proteolysis, which may
accelerate preexisting chronic diseases or
trigger a new chronic impairment.
Pneumonia appears to activate the
proteasome–ubiquitin pathway and cause
muscle fiber degradation that may last
beyond the pulmonary syndrome,
particularly in elderly patients (50, 51).
Alterations in the normal lung microbiome
after infection or as a result of treatment
may be causative or an amplifier of this
dysregulated resolution (58), similar to that
documented for the gut microbiome and
for respiratory tract infections in chronic
respiratory conditions such as asthma,
cystic fibrosis, idiopathic pulmonary
fibrosis, and bronchiectasis (59–61). How
biological changes during pneumonia
connect to longer-term consequences of
pneumonia is an important question that is
only beginning to be addressed (Figure 1).
Determining the functional significance
and clinical utility of such connections (e.g.,
as biomarkers and druggable targets) may
yield novel approaches to preventing
decline after pneumonia.
Finally, a bidirectional relationship
between pneumonia and underlying
diseases appears to be operative.
Interactions with CVD (53, 62), chronic
lung disease (63), neurocognitive function
(52), and skeletal muscle (50) may lead to
an iterative feedforward interaction
between pneumonia and chronic diseases
that accelerates physiologic decline, drives
the process of unhealthy aging, and hastens
mortality through these chronic
complications (8).
To understand the mechanisms linking
pneumonia to extrapulmonary disease and
determine its impact on short- and long-
term outcomes, the working group defined
these goals (Table 1):
1. Elucidate how the lung immune
response to pneumonia relates to the
systemic inflammatory response and
manifests in cardiac, neurological,
muscular, psychological and other
diseases
2. Identify markers of pneumonia severity
and host response that predict long-





The sections above reflect topics and
recommendations particular to each
discrete section of the workshop. In
addition, themes emerged that spanned all
sessions and became prominent topics in the
general discussion session that concluded
the workshop. These are summarized below.
Host-focused Clinical Approaches to
Pneumonia
The optimal treatment for pneumonia
should involve identifying the host process(es)
dysregulated in the individual patient
and providing host-directed therapies that
counter the dysregulated process(es). This
requires better endotyping of patients with
pneumonia combined with better host-
directed therapies (Table 2).
The current lack of effective host-
focused endotyping for pneumonia is a
major shortcoming. Current pneumonia
typing strategies differentiate patients by
the microbes present (e.g., influenza,
pneumococcus, or Acinetobacter), by the
setting in which pneumonia developed (e.g.,
community-acquired pneumonia,
healthcare-associated pneumonia, or
ventilator-associated pneumonia) (64), or
by pneumonia severity using any of many
available clinical scoring systems (65).
These have utility for guiding antimicrobial
use, but they do not report on or guide
responses to the host biology driving
pneumonia pathogenesis. Immunoparalysis
has been inferred as one possible
endotype of pneumonia, based on blood
transcriptome differences interpreted to
reflect decreases in antigen presentation,
TLR (Toll-like receptor) signaling, or B-cell
development, or increases in T-cell
exhaustion or endotoxin tolerance (66);
its clinical utility is intriguing but
speculative. Severe pneumonia with a strong
inflammatory response has been proposed
as an endotype useful for guiding therapy,
defined in one clinical trial by a serum
C-reactive protein threshold (67). Additional
host endotypes yet to be defined could
have important clinical implications for
pneumonia. A few possible examples of
endotypes that may emerge include
dysregulations of innate immune
pathways (such as excess or inadequate
inflammasome activity), dysfunctions of
Table 2. Overarching Priority Areas in Pneumonia Research
Connect endotyping with host-directed
therapies
Use clinical and biological data to establish
and better delineate endotypes of
pneumonia
Develop metrics for assigning endotypes to
individual patients
Test abilities of already available host-directed
therapies to improve pneumonia treatment,
guided by endotype
Develop and test novel endotype-directed
therapies for pneumonia, based on advances
in mechanistic understanding
Generate predictive tools for pneumonia For those with risk factors, develop
measurements that discriminate who will
most likely get pneumonia
For those with pneumonia, develop
measurements that discriminate who will
most likely experience clinical failure
For those recovering, develop measurements
that discriminate who will most likely have
recurrence, cardiovascular events, pulmonary
decrements, cognitive decline, or other
sequelae
Elucidate defense mechanisms in the
protected lung
Refine, improve, or develop alternatives
for approaches to better studying the
protected lung
Determine how lung defense is affected by
earlier life experiences, including antecedent
respiratory infections
Define defense roles of cells within the lung
interstitium
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select cell types (such as airway epithelial
antimicrobial activities), or alterations
of processes beyond inflammation and
immunity (such as repair and regeneration
pathways for lung tissue). However,
endotyping pneumonia is currently in a
nascent stage and needs to be greatly
expanded to become more precise, more
sophisticated, and more clinically useful.
All three sessions of the working group
stressed a need for greater abilities to
subdivide at-risk subjects, patients with
pneumonia, and pneumonia survivors
into meaningful endotypes that
report underlying physiologic processes
responsible for pneumonia susceptibility
and/or outcomes at the individual-patient
level.
Host-directed therapeutic approaches
against pneumonia appear promising but
are today largely unrealized. Therapies in
clinical practice may prove useful, but
when and how they should be used
for pneumonia are uncertain. These
include antiinflammatory agents
(such as corticosteroids, nonsteroidal
antiinflammatory drugs, macrolides,
inhibitors of proinflammatory cytokines
such as tumor necrosis factor or IL-1, and
more), immunostimulatory agents (such
as checkpoint inhibitors, recombinant
proinflammatory cytokines such as IFN-g,
and more), proresolving agents (such
as aspirin or polyunsaturated fatty
acid–derived specialized proresolving
mediators), and others with pneumonia-
relevant physiologic effects (such as statins,
glitazones, angiotensin-converting enzyme
inhibitors, and more). Effectively testing
such host-focused agents will require
abilities to endotype patients with
pneumonia for host processes contributing
to pathophysiology. In addition,
novel host-directed therapies are needed.
Preclinical examples discussed in the
workshop included improvements in
immune resistance against pneumonia
resulting from epithelial stimulation
by ligands for TLR2 and TLR9 (68),
improvements in tissue resilience against
pneumonia in the elderly by transfer
of alveolar macrophages (7), and
improvements in both immune resistance
and tissue resilience during pneumonia
resulting from systemic administration
of aspirin-triggered resolvin D1 (34).
Whether these examples will eventually
prove to enhance clinical pneumonia
outcomes is yet to be determined, but
they illustrate that diverse new types
of approaches to enhancing the host
response should be considered and
tested. Improved understanding of
mechanisms of lung defense against
pneumonia, and how defenses change
in those at risk for or recovering from
pneumonia, will yield new host-
focused strategies for pharmacologically
bolstering immune resistance and tissue
resilience.
Predictive Tools for Pneumonia
Susceptibility and Outcome
A theme emerging across all three
sessions was the need for methods that
discriminate those patients likely to
decline over time, and in which specific
ways, compared with others with a more
favorable course (Table 2). This applies to
individuals who are at risk for, have, or are
recovering from pneumonia. Although
temporal perspective was central to the
organization of the workshop, all three
sessions stressed a frustratingly poor
ability to predict the future course for any
individual subject, including which of those
with risk factors (e.g., COPD, Parkinson’s
disease, and diabetes) will later develop
pneumonia, which of those with
pneumonia will later demand more urgent
attention (e.g., critical care or mechanical
ventilation) and when, and which of those
who recover from pneumonia will later
experience adverse outcomes (e.g.,
infarctions, fibrosis, or depression). Attempts
have been made to predict clinical failure
during pneumonia, but none yet are
satisfactory (69). For subjects at risk for or
recovering from pneumonia, attention to
generating predictive systems has been
limited (55, 70, 71). Much more research is
required, with computational and machine
learning approaches presenting especially
exciting opportunities in this realm. In
addition to creative computational
approaches, clinical cohorts and biological
models especially well suited to these
questions are needed. New strategies need
to be derived and then tested for predicting
pneumonia in those at risk, for predicting
progression or clinical failure in those
with pneumonia, and for predicting
adverse events in those who recover from
pneumonia. Such predictive tools will aid in
the development and application of host-
based interventions designed to prevent
pneumonia and its short- and long-term
sequelae.
Elucidating Mechanisms of Pneumonia
Defense in the Protected Lung of
Young, Healthy Adults
A better understanding of the mechanistic
pathways that effectively prevent
pneumonia in most young adults with
respiratory infections (Table 2) will
advance all of the goals discussed above.
Major knowledge gaps in pneumonia
biology stem in part from how pneumonia
defenses are traditionally studied using
human subjects and animal models.
Approaches need to be reconsidered and
complemented. Human studies have been
driven in large part by accessibility,
typically relying on available clinical data or
samples collected by venipuncture or
bronchoscopy. However, major components
of the host defense pivotal to
pneumonia prevention are poorly
illuminated using these approaches, such as
the lymphocytes residing in the lung
interstitium (8). More studies are needed of
cells located within human lungs, to
discover their regulation and functions
related to pneumonia defense. Animal
studies are driven in large part by analyzing
subjects with unnaturally clean histories,
often in specific-pathogen-free facilities
where they have had few or likely no past
infections. However, major components of
host defenses pivotal to pneumonia
prevention arise only after repeated
respiratory infections, such as adaptive
immunity driven by central memory and
lung-resident memory cells as well as
trained innate immunity from lung epithelial
cells and macrophages (8). More lung
defense research needs to incorporate
models with relevant exposure histories to
dissect the roles of such acquired defense
mechanisms. Although much remains
to be learned from traditional avenues,
alternative approaches must also be pursued
to elucidate mechanisms of pneumonia
defense that are lung localized and exposure
driven, both of which are poorly understood
currently but pivotal to the lower pneumonia
rates observed in healthy young adults.
Improved understanding of the normal
defenses against pneumonia in young,
healthy lungs is key to investigating
compromises due to advancing age; chronic
diseases and conditions; and noninfectious
exposures such as cigarette smoke, air
pollution, and alcohol. It will rationally
guide studies related to predictive tools, to
endotyping, and to host-directed therapies.
It will provide new targets for discriminating
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individual host susceptibility and guide
strategies to counteract that. If failures of
specific pneumonia defense mechanisms
contribute to complications arising later and
elsewhere, then addressing these knowledge
gaps will raise new opportunities for
differentiating which patients are at risk for
accelerated decline and for interventions to
prevent complications. In short, virtually all
of the goals outlined in this workshop
would be informed by greater mechanistic
understanding of how pneumonia is typically
avoided when healthy, young lungs are infected.
Conclusions
A diverse assembly of investigators
concluded that now is an exceptionally
exciting time for pneumonia research,
identifying research priorities that are
especially pressing, opportune, and likely
to make profound differences. Major
suggestions involved reenvisioning
pneumonia as more than just an acute
lower respiratory tract infection;
pneumonia results from dysregulations
of host defense that precede and potentially
predict infection, and pneumonia sequelae
can appear much later and in organs
beyond the lung. Although microbes
are recognized as essential triggers, the
emphasis is that host biology is
paramount to developing and recovering
from pneumonia. The group made
several specific suggestions related to
each of the sessions focusing on
before (“susceptibility”), during (“host
response”), and after (“consequences”)
pneumonia. Common themes arose across
sessions, including the need for better
endotyping of patients with pneumonia
as well as those susceptible to or
recovered from pneumonia, and for
measuring longitudinally host
functional or dysfunctional activities
before, during, and after pneumonia.
A few overarching goals emerged that
should be highlighted for special
attention from researchers interested in
pneumonia: improving the types and
targeting of host-focused clinical
approaches for preventing and treating
pneumonia; generating tools that
predict pneumonia occurrence,
severity, and outcomes; and defining
mechanisms of immune resistance
and tissue resilience that
normally prevent pneumonia during
infection. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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